Brent Compton, MD
Interventional Pain Medicine · The Villages, FLNPI 1043554439
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,009 of the $18,575 with a category attached, or 64.6%. 29 manufacturers reported payments, led by Boston Scientific at 30.5% of the total. 2025 is the largest year on record at $7,273, more than ten times the $210 reported in 2019.
Across 230 payments — averaging $80.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$6K
- Abbott$3K
- Stryker$3K
- Medtronic$2K
- Surgentec$673
- Foundation Fusion Solutions, LLC$615
- plus $3K from 23 others
Across 4 payments — averaging $9659.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mesoblast, Inc.$39K
What the payments were for
- Consulting fees$6924%
- Travel & lodging$5,75231%
- Food & beverage$12,00965%
- Entertainment$1231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 94 | $5,670 |
| Abbott | 16 | $3,318 |
| Stryker | 12 | $2,823 |
| Medtronic | 26 | $2,075 |
| Surgentec | 1 | $673 |
| Foundation Fusion Solutions, LLC | 14 | $615 |
| Saluda Medical Americas, Inc. | 8 | $456 |
| Si-bone, Inc. | 6 | $448 |
| Globus Medical | 8 | $352 |
| Nevro Corp. | 6 | $315 |
| Spinal Simplicity, LLC | 3 | $298 |
| SPR Therapeutics, Inc | 5 | $217 |
| Amarin Pharma, Inc. | 2 | $206 |
| Mesoblast, Inc. | 1 | $178 |
| Vertos Medical, Inc. | 2 | $169 |
| Radius Health, Inc. | 1 | $121 |
| Collegium Pharmaceutical, Inc. | 4 | $88 |
| Chiesi USA, Inc. | 1 | $84 |
| Averitas Pharma Inc. | 2 | $77 |
| Lilly USA, LLC | 4 | $68 |
| AbbVie | 2 | $64 |
| Nalu Medical, Inc. | 3 | $54 |
| Bioventus LLC | 2 | $45 |
| CSL Behring | 2 | $37 |
| Merz Pharmaceuticals, LLC | 1 | $34 |
| Boehringer Ingelheim | 1 | $33 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| MML US, Inc. | 1 | $19 |
| GRT US Holding, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$2,880
- mild Device Kit$2,198
- GENERAL PAIN MANAGEMENT$1,039
- SYNCHROMEDII$856
- WaveWriter Alpha Prime 16$807
- Osteoflo$673
- HA MINUTEMAN G3-R$270
- Intracept$247
- Senza$237
- Superion Indirect Decompression System$180
- Ryoncil$178
- KYPHON EXPRESS II KYPHOPAK TRAY$174
- INTELLIS ADAPTIVESTIM$154
- Vyrsa V1$142
- Evoke$122
- Tymlos$121
- Vascepa$116
- Evoke SCS$105
How this compares
$18,575 in reported general payments places this provider in the 85th percentile of 278 interventional pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 12 | $13,132 |
| LyricaPregabalin | 11 | $11,362 |
| Xtampza ErOxycodone Myristate | 11 | $9,086 |
| Emgality PenGalcanezumab-Gnlm | 11 | $8,074 |
| Pregabalin | 167 | $3,779 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 129 | $3,330 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 120 | $3,287 |
| Morphine Sulfate ErMorphine Sulfate | 25 | $1,431 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 89 | $1,133 |
| Duloxetine Hcl | 55 | $596 |
| Tizanidine Hcl | 90 | $571 |
| Gabapentin | 41 | $538 |
| Morphine Sulfate | 27 | $533 |
| Memantine Hcl | 41 | $532 |
| Cyclobenzaprine Hcl | 27 | $527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $88 | $9,08611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 278 interventional pain medicine providers in Florida.
Other interventional pain medicine in The Villages
- Louis RasoJupiter$1.3M
- Ajay AntonyGainesville$1.1M
- Michael EspositoVero Beach$777K
- Nomen AzeemRiverview$650K
- Stanley GolovacMerritt Island$367K
- Sunil PanchalLutz$363K
- Robert BallPort Charlotte$246K
- Justin MannJacksonville$243K
- Giuseppe PaeseBoca Raton$180K
- Miguel de la GarzaNew Port Richey$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.